Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAM trial: adjuvant tamoxifen versus exemestane in early hormone receptor-positive breast cancer
NL-OMON22587Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in breast cancer comparing Upfront exemestane with Sequential tamoxifen then exemestane (2 arms). Primary endpoint: Relapse-free survival at 2.75 years. Started Jul 2001; status: active, not recruiting.
02
Drugs
exemestanetamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON22587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22587.